GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: AK-120 | AK120
Compound class:
Antibody
Comment: Manfidokimab (AK120) is a humanized IgG4 monoclonal antibody that targets the IL-4 receptor alpha (IL-4Rα) subunit of the IL-4 and IL-13 receptor complexes. It was designed to block pathological T helper 2 (Th2)-mediated inflammatory responses initiated by the IL-4 and IL-13 cytokines.
|
| No information available. |
Summary of Clinical Use  |
| Manfidokimab (AK120) is a clinical candidate for the treatment of atopic dermatitis. Clinical development for asthma was terminated (for stragtegic/business reasons). |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06092762 | A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis | Phase 2 Interventional | Akeso | ||
| NCT06383468 | A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis | Phase 3 Interventional | Akeso | ||
| NCT06700499 | A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis | Phase 2 Interventional | Akeso | ||
| NCT04256174 | A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis | Phase 1 Interventional | Akeso | 1 | |
